Trial Profile
An 8 Week, Double-blind, Randomized, Parallel-group Study to Compare the Effect of Aliskiren 300mg + Valsartan 320mg vs. Telmisartan 80mg + Ramipril 10mg on Biomarkers of the Renin-angiotensin-aldosterone System in Moderate Hypertension.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Aliskiren (Primary) ; Valsartan (Primary) ; Ramipril; Telmisartan
- Indications Hypertension
- Focus Biomarker; Therapeutic Use
- 18 Feb 2010 Actual patient number (88) added as reported by ClinicalTrials.gov.
- 18 Feb 2010 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
- 21 Jul 2009 New trial record